Marker Therapeutics (MRKR) Non Operating Interest Expenses (2010 - 2014)

Marker Therapeutics (MRKR) has reported Non Operating Interest Expenses for 5 consecutive years, with $15425.0 the latest figure, recorded in Q3 2014.

• On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $15425.0 in Q3 2014; TTM through Sep 2014 was $485828.0, a N/A change from a year earlier, with the FY2015 full-year figure at $10925.0, changed N/A from the prior year.
• Non Operating Interest Expenses was $15425.0 for Q3 2014 at Marker Therapeutics, down from $35269.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $458565.0 in Q3 2010 and troughed at $15425.0 in Q3 2014.
• A 5-year average of $194780.7 and a median of $112247.5 in 2011 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses jumped 246.22% in 2013 and sank 89.47% in 2014, its largest moves.
• Over 5 years, Non Operating Interest Expenses stood at $446660.0 in 2010, then slumped by 72.96% to $120755.0 in 2011, then declined by 16.98% to $100246.0 in 2012, then surged by 234.07% to $334888.0 in 2013, then slumped by 95.39% to $15425.0 in 2014.
• The last three Non Operating Interest Expenses figures came in at $15425.0 (Q3 2014), $35269.0 (Q1 2014), and $334888.0 (Q1 2013), per Business Quant data.